Business
ORAGENICS INC: Overview We are a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases.
Net income increased 6.9% to ($9.8M), while Operating cash flow decreased 7.5% to ($9.2M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($9.8M)Watch
- Cash generation — Free cash flow N/ANote
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 1 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From ORAGENICS INC's own filings, the day they're filed.
- Natasha Giordano · Board Chair for Incora Health · appointmenteff. 2025-09-01
- Natasha Giordano · Directors · appointmenteff. 2025-09-01
- J. Michael Redmond · Chief Financial Officer · departureeff. 2024-12-16
Latest filings
- 8-K · Company announcement2026-08-28
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-06
- DEF 14A · Annual proxy (pay & governance)2026-05-20
- 8-K · Company announcement2026-05-19
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ORAGENICS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.